FlowCardia, Inc. Appoints Deborah DeFilippo CFO - Gilde Healthcare

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

June 18, 2008

SUNNYVALE, Calif., June 18, 2008 — FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer. Ms. DeFilippo comes to FlowCardia with over 19 years of experience in Medical Devices. 

Most recently, Ms. DeFilippo served as Chief Financial Officer and Vice President, Business Development for the Guidant Cardiac Surgery business. Prior to that, she held a variety of executive positions at Guidant divisions as well as the Corporate Office of Guidant. Earlier, Ms. DeFilippo was the Director of Finance and Information Systems at Devices for Vascular Intervention prior to DVI’s acquisition by Guidant. Ms. DeFilippo holds a B.A. from Stanford University.

“We are tremendously pleased that Deborah will be joining FlowCardia. She is not only a very experienced financial executive but has also overseen such functions as Strategic Planning, Information Systems and Business Reengineering during her time with Guidant,”

said Wick Goodspeed, President and CEO of FlowCardia.

“Deborah will be a great addition to our management team and a substantial contributor to our sales growth and transition to profitability over the next few years.”

“I’m thrilled to be returning to the medical device field and joining FlowCardia at such an exciting time,”

said Ms. DeFilippo.

“FlowCardia is growing rapidly in its first year of commercialization and I am enthusiastic about the opportunity to help the Company become the leading CTO Device Company in the world.”

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture endovascular CTO recanalization systems. Additional information is available on the Company’s Web Site at www.flowcardia.com.

CONTACT
Mark Page
Sr. Director Marketing
FlowCardia, Inc.
T: 408-617-0352 ext. 301

SOURCE
FlowCardia, Inc.

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...
May 4, 2022